Abstract: A back plate unit includes a back plate having opposite first and second sides, an optical member mounted to the back plate, and a buffer assembly disposed between the optical member and the back plate and including at least one first buffer member disposed on the first side and made of a thermoplastic material, and at least one second buffer member disposed on the second side and made of a thermoset material. The at least one first buffer member and the optical member are deformed when heated, and the at least one first buffer member is squeezed and compressed by expansion of the optical member. A backlight module of a display device is also disclosed.

Abstract: A back plate unit includes a back plate having opposite first and second sides, an optical member mounted to the back plate, and a buffer assembly disposed between the optical member and the back plate and including at least one first buffer member disposed on the first side and made of a thermoplastic material, and at least one second buffer member disposed on the second side and made of a thermoset material. The at least one first buffer member and the optical member are deformed when heated, and the at least one first buffer member is squeezed and compressed by expansion of the optical member. A backlight module of a display device is also disclosed.

Abstract: A method for reducing an established metastatic tumor, comprising administering an effective amount of a pharmaceutical composition to a subject in need, wherein the pharmaceutical composition comprises a polypeptide of a fibronectin-binding domain of dipeptidyl peptidase IV having a maltose-binding protein (MBP) fused at an N-terminal thereof, a cross-linking molecule, an active agent, and a pharmaceutically acceptable carrier.

Abstract: A method and biomarker for evaluating metastasis, and an siRNA compound for inhibiting metastasis. The method of the present invention includes: providing a sample of a subject, which includes a normal tissue and a tissue to be detected; detecting expression of a biomarker of the normal tissue and the tissue to be detected, respectively, wherein the biological marker is SERPINA1; and comparing the expression of the biological marker of the normal tissue and the tissue to be detected. When the expression of the biological marker of the tissue to be detected is higher than the normal tissue, it represents that the subject is at a risk of suffering from metastasis.